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ABSTRACT 
Many antibiotics inhibit bacterial growth by binding to the ribosome and interfering with protein 
biosynthesis. Macrolides represent one of the most successful classes of ribosome-targeting 
antibiotics. The main clinically-relevant mechanism of resistance to macrolides widely employed 
by pathogens is dimethylation of the 23S rRNA nucleotide A2058 located in the drug binding site, 
a reaction catalyzed by the Erm-type rRNA methyltransferases. Here, we present the first crystal 
structure of the Erm-dimethylated 70S ribosome at 2.4Å resolution together with the structures of 
unmethylated 70S ribosome functional complexes alone and in combination with several 
macrolides. Altogether, our structural data do not support the previous models proposed to explain 
Erm-mediated mechanism of macrolide resistance. Instead, we present a principally new 
explanation of how A2058-dimethylation confers resistance to macrolides. Moreover, our high-
resolution structures of two macrolide antibiotics bound to the unmodified ribosome revealed a 
previously unknown role of the universal desosamine moiety in drug binding. The newly 
understood mode of interaction of macrolide’s desosamine with the ribosome lays a foundation 
for the rational knowledge-based design of macrolides that can overcome Erm-mediated resistance. 
 
KEYWORDS 
Macrolide; antibiotic; resistance; methylation; A2058; 23S rRNA; 70S ribosome; X-ray structure; 
inhibition of translation; peptidyl transferase center; nascent peptide exit tunnel. 
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INTRODUCTION 
Antibiotics prevent bacterial growth by inhibition of vital cellular processes. Many of them target 
functionally important sites on the bacterial 70S ribosome and block protein synthesis1. Prominent 
among these inhibitors are macrolide antibiotics, a large family of natural and semi-synthetic 
compounds that consist of 12- to 16-membered macrolactone rings decorated with various side 
chains. Macrolides are widely used for the treatment of human community-acquired bacterial 
respiratory tract infections, including those that arise as complications of viral diseases2,3. These 
antibacterials achieve their inhibitory action by binding in the nascent peptide exit tunnel (NPET) 
of the bacterial ribosome and interfering with the progression of some growing polypeptides 
through this tunnel4. Several mechanisms of resistance to macrolides have been described, 
including efflux5,6, enzymatic degradation of the drugs7,8, or alteration of the drug-binding pocket 
through mutations6,9. However, the most abundant among bacterial pathogens and clinically most 
relevant mechanism of resistance against macrolides is based on mono- or dimethylation of the N6 
position of a specific adenine residue (A2058) of the 23S rRNA (E. coli numbering of the 
nucleotides is used throughout) (Fig. 1a)10-12. The modification of this nucleotide located in the 
macrolide binding pocket in the NPET is catalyzed by the Erm-type rRNA methyltransferases13,14. 
Dimethylation, in particular, dramatically reduces the binding of the macrolides to the ribosome, 
rendering cells highly resistant to these drugs15,16. In addition to macrolides, the same modification 
confers resistance to two other structurally-unrelated classes of ribosome-targeting antibiotics, 
which also bind in the NPET, specifically lincosamides and streptogramins B (hence this type of 
resistance is known as MLSB)17. 
Significant efforts have been invested in developing newer generations of semi-synthetic 
macrolide antibiotics with improved binding properties, e.g. ketolides2. These drugs show 
improved activity against a variety of Gram-positive and Gram-negative pathogens, including 
those carrying inducible erm genes3,18. Nevertheless, bacteria that constitutively express Erm-
methyltransferase enzymes that dimethylate A2058 still demonstrate high levels of resistance to 
all the known macrolide antibiotics19,20. Therefore, there is a pressing demand for the development 
of new macrolides active against Erm-modified ribosomes of resistant pathogens. Understanding 
at a structural level the detailed molecular mechanism of Erm-mediated resistance to macrolides 
would provide key insights that are essential for the development of such compounds. 
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Previous attempts to explain the effect of A2058-methylation on drug binding were based on the 
structures of unmodified bacterial ribosomes complexed with various macrolides21-26. According 
to the prevailing steric clash model, the positions of the methyl group(s) added to the exocyclic 
N6 amino group of A2058 would overlap either with the 2´-hydroxyl group or the dimethyl-amino 
group of the desosamine sugar of a macrolide21. Due to this collision, the drug molecule should be 
unable to fully accommodate into its binding pocket and form hydrogen (H-) bond(s) with the 
A2058 and, therefore, cannot stably bind to the Erm-modified ribosome. However, the simplistic 
steric clash model is hard to be reconciled with the available experimental data. For instance, 
macrolide derivatives with 2´-deoxy or 3´-desmethyl desosamine, which were designed to reduce 
the steric clash with dimethylated A2058, were inactive against Staphylococcus aureus strains 
constitutively expressing Erm methyltransferase27. An alternative model is based on molecular 
dynamics simulation studies that suggest methylation of A2058 would result in complex structural 
rearrangements of the entire macrolide binding pocket, making drug binding impossible28. This 
model could rationalize the observed Erm-mediated resistance to all antibiotics of the MLSB group, 
macrolides, lincosamides, and streptogramins B, which bind at the overlapping sites within the 
NPET of the bacterial ribosome. Although an attractive hypothesis, such structural rearrangements 
have never been experimentally verified or observed structurally. 
By finding the conditions for expressing functionally-active Erm-methyltransferase in 
thermophilic bacterium Thermus thermophilus, and solving the structures of the Erm-modified 
(A2058-dimethylated) and unmethylated 70S ribosome in complex with mRNA and 
aminoacylated tRNAs alone and in combination with macrolides, we demonstrate that neither of 
these models is likely to be correct. Instead, we present a principally new explanation of how 
A2058-dimethylation confers resistance to macrolide antibiotics. Not only we uncovered the 
mechanism of Erm-mediated macrolide resistance, but also our high-resolution structures of two 
macrolide antibiotics bound to the unmodified ribosome revealed a previously unknown role of 
the universal desosamine side chain in drug binding. The newly understood mode of interaction of 
this macrolide’s moiety with the ribosome provides pivotal information for the design of 
macrolides that can overcome Erm-mediated resistance. 
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RESULTS AND DISCUSSION 
Engineering of the T. thermophilus strain expressing active Erm rRNA methyltrasnferase. 
Erm enzymes are expressed in a broad spectrum of pathogenic bacterial clinical isolates as well as 
in non-pathogenic native bacterial species where they produce strong resistance to macrolides29. 
The Erm methyltransferase operates during ribosome assembly because in the mature ribosome 
the target of Erm action, A2058 of the 23S rRNA, is inaccessible to the enzyme30. To obtain a 
structure of the Erm-modified ribosome, we have chosen the Gram-negative thermophilic 
bacterium T. thermophilus (Tth) as our experimental model because Tth ribosomes have been 
successfully used in the past for structure determination and produce the highest-resolution 
data31,32. However, our attempts to express a functionally active Erm enzyme PikR2 from the 
mesophilic bacterium Streptomyces venezuelae33 in this thermophilic host have failed, presumably 
due to protein instability at high growth temperature (Supplementary Table 1). To overcome this 
problem, we selected four erm-like genes from genomes of bacteria adapted for growth at elevated 
temperatures (Fig. 1b; Supplementary Figs. 1, 2; Supplementary Table 1). The genes were 
synthesized, cloned into the pBGAA1 vector34 and expressed in T. thermophilus (Fig. 1c). 
Macrolide susceptibility testing of the plasmid-transformed Tth cells showed that the expression 
of an erm-like gene from Bifidobacterium thermophilum (referred hereafter as ErmBth) resulted 
in a strong resistance to the macrolide antibiotic erythromycin (ERY) increasing the minimal 
inhibitory concentration (MICERY) for the ErmBth-expressing cells 1000-fold compared with the 
control cells carrying the empty vector (Supplementary Table 2). 
To verify that the observed macrolide resistance results from the specific methyltransferase 
activity of ErmBth, we used a primer extension analysis to biochemically assess A2058 
modification35. This method is based on the arrest of reverse transcriptase (RT) progression on the 
rRNA template due to its inability to incorporate a complementary nucleotide into the synthesized 
cDNA at the N6-dimetylated adenine. The expected cDNA arrest product of the RT reaction 
corresponding to the A2058 position was observed only on the 23S rRNA isolated from the Tth 
cells expressing ErmBth (Fig. 1d, lanes 2 and 3), confirming that ErmBth has the desired A2058-
targeting methylation activity. Moreover, we found that the level of A2058-dimethylation can be 
significantly increased by growing the ErmBth-expressing cells in the presence of sub-inhibitory 
concentrations of ERY (Fig. 1d, e). By optimizing ERY concentration and growth temperature of 
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the ErmBth-expressing T. thermophilus strain, we managed to reach the level of A2058 
dimethylation as high as ~60% (Fig. 1e). Since X-ray crystallography is essentially an averaging 
technique, structural data could be confidently interpreted even if only half of the ribosomes are 
N6-dimethylated at A2058. 
 
Structure of the m62A2058 70S ribosome. 
We used our T. thermophilus strain expressing ErmBth-methyltransferase to purify 70S ribosomes 
for structural analysis. These were crystallized using previously published conditions31,36 in a 
functional state that corresponds to a pre-peptide bond formation state of the ribosome, in which 
unreacted fMet-tRNAiMet (in the form of its non-hydrolyzable analog fMet-NH-tRNAiMet) occupies 
the P-site, while non-hydrolyzable Phe-NH-tRNAPhe is bound to the A-site. By applying our recent 
improvements in complex preparation (see Materials and Methods), we were able to obtain crystal 
structures of the A2058-dimethylated and unmethylated Tth 70S ribosome in complex with mRNA 
and aminoacylated tRNAs determined at 2.4Å and 2.5Å resolution, respectively (Supplementary 
Table 3). For a more accurate understanding of drug-ribosome interactions, we determined 
structures of the unmethylated ribosomal functional complexes bound with two macrolide 
antibiotics, telithromycin (TEL) or erythromycin (ERY). These structures have been solved at 
2.6Å and 2.55Å resolution, respectively, and represent the highest resolution 70S ribosome-
macrolide structures available to date (Supplementary Table 3). 
At this resolution, methylation of nucleotide bases can be directly visualized in the unbiased 
electron density maps (Fig. 2a, green mesh), and the N6-dimethylated A2058 (m62A2058) can be 
confidently modeled in our structure (Fig. 2a, b; Supplementary Fig. 3a). Due to the presence of 
aminoacylated tRNAs (Supplementary Fig. 4), our structure of the WT ribosome with the 
unmodified A2058 reached a higher resolution than the previously reported structure36, and clearly 
shows the position and orientation of the unmethylated A2058 residue which, therefore, serves as 
our reference point (Fig. 2c, d). Additional evidence for the presence of the methyl groups on 
m62A2058 comes from the comparison of electron densities for the methylated m62A2058 and the 
unmethylated A2057 in the 23S rRNA (negative control, Supplementary Fig. 3b) or the N6-
dimethylated A1519 in the 16S rRNA (positive control, Supplementary Fig. 3c) of the same 
structure. In contrast to the predictions of MD simulations that A2058 modification would lead to 
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a dramatic rearrangement of the macrolide binding site28, no significant changes were observed in 
the orientations of the 23S rRNA nucleotides or the amino acid residues of the ribosomal proteins 
L4 and L22 neighboring A2058 in the ErmBth-modified ribosome (Fig. 3a, b). Most importantly, 
m62A2058 appears in the same orientation relative to its neighbors as compared to the reference 
(unmodified) structure (Fig. 3c, d). Because A2058 methylation has been proposed to cause long-
range structural rearrangements and affect the functionality of the ribosome28, we also examined 
the ErmBth-modified ribosome for shifts in any of the key functional nucleotides around the PTC 
but failed to find any changes. Altogether our high-resolution structure of the A2058-dimethylated 
ribosome shows that the Erm-catalyzed rRNA modification does not cause any significant 
structural rearrangements in the macrolide binding site in the NPET. 
Despite the fact that macrolide antibiotics have many H-bond donors and acceptors (Fig. 4a), there 
is only a single H-bond (between the 2´- OH of the desosamine sugar of a macrolide and the N1 
atom of the A2058) that has been consistently observed in all structures of ribosome-bound 
macrolides (Fig. 4b)21-25,32. It has been suggested previously that the methyl groups of the N6-
dimethylated A2058 residue can sterically clash with either the 2´-OH or the 3´-dimethyl-amino 
group of desosamine, leading to disruption of this critical H-bond and disturbing macrolide 
binding21,22. However, superposition of our structure of A2058-dimethylated Tth ribosome with 
that of the unmethylated Tth ribosome bound to ERY (or TEL) shows no overlap between the 
m62A2058 methyl groups and the desosamine 2´-OH (Fig. 4b, c) or the desosamine dimethyl-
amino groups (Fig. 4b, d). It is important to point out that, because the N6-nitrogen of the N6-
dimethylated (and also N6-monomethylated) adenine residue has sp2 geometry37,38, the two methyl 
groups attached to the exocyclic amine of m62A2058 are planar with the adenine heterocycle ring. 
Furthermore, the sp2 geometry of the N6-atom does not allow free rotation around the C6-N6 bond 
in m62A2058, excluding any alternative orientations of the methyl groups that could potentially 
result in a sterical clash with a macrolide. Thus, the analysis of the high-resolution structures of 
the ribosome-bound macrolides in complex with the unmodified ribosome and antibiotic-free 
A2058-dimethylated ribosome brings us to the conclusion that dimethylation of the exocyclic 
amine of A2058 by Erm methyltransferase does not result in a steric clash with desosamine sugar 
of the macrolide antibiotic or the loss of the H-bond between the desosamine 2´-OH and the A2058 
residue proposed previously to explain Erm-mediated resistance to macrolides. 
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Deciphering the role of the desosamine dimethyl-amino group in macrolide binding. 
The dimethyl-amino group of desosamine has been shown previously to be crucial for the 
interaction of macrolides with the ribosome39. However, its exact role in drug binding has never 
been revealed. It is evident from the previous structural studies that no ribosomal component is 
directly involved in the interaction with this group. Moreover, by comparing all the available 
structures of ribosome-macrolide complexes, we noticed a significant variability in the orientation 
of this chemical group (Supplementary Figs. 5, 6), possibly due to varying interpretations of the 
electron density maps rather than differential placement of this chemical moiety. Notably, in none 
of the previous structures 3´-dimethyl-amino group of desosamine directly interacts with any of 
the ribosome counterparts. 
In our 2.55Å and 2.6Å resolution structures of ribosome-bound ERY or TEL, both drug molecules 
are located in the canonical macrolide-binding pocket in the NPET near the PTC23-25. Interestingly, 
the shape of the electron density around the desosamine dimethyl-amino group clearly shows that 
the nitrogen lone pair of electrons (and this group as a whole) is pointed in the direction of A2058 
(Fig. 5a, b, middle insets; Supplementary Fig. 7). This orientation is different from that in some 
of the previous structures, in which this group is oriented towards the exocyclic N6-amino group 
of the adjacent A2059 (Supplementary Fig. 6a, b)22-25,32,40. However, it resembles the orientation 
of this moiety in the 2.4Å-resolution structure of azithromycin bound to Haloarcula marismortui 
50S ribosomal subunit (Supplementary Fig. 6c)22 or the 3.0Å- resolution structure of this 
macrolide bound to Tth 70S ribosome (Supplementary Fig. 6d)23. 
Importantly, the high quality of the electron density maps of the new 70S-ERY and 70S-TEL 
structures allowed us to detect a distinct peak of positive electron density in close proximity to the 
dimethyl-amino moiety of desosamine in both complexes (Fig. 5a, b). We interpreted this electron 
density as a tightly coordinated water molecule based on the following criteria: (i) it fits snuggly 
between the two potential H-bond acceptors (nitrogen of the dimethyl-amino group of desosamine 
and one of the non-bridging oxygens of the G2505 phosphate) and a strong H-bond donor 
(exocyclic N6 amino group of the A2058); (ii) the distances between the aforementioned atoms 
and a putative water molecule in this location are all within the ideal range for H-bonds (2.5-3.5Å); 
(iii) the orientations of the proposed H-bonds correspond to the ideal tetrahedral geometry of the 
sp3-hybridized oxygen atom of a water molecule (Fig. 5a, b); (iv) ideal planar geometry with the 
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heterocycle ring for the H-bond from the A2058 N6 donor to the oxygen acceptor of the modeled 
water (Fig. 5a, b, middle insets); (v) the observed electron density is too weak to be attributed to 
more electron-dense ions, such as Mg2+ or K+. Thus, because of the high resolution of our new 
70S-ERY and 70S-TEL structures, it becomes evident that the high affinity of desosamine-
containing macrolides to the ribosome is mediated by a strong H-bond mediated by the water 
molecule, which in turn is tightly coordinated by the exocyclic N6-amino group of A2058 and the 
phosphate of G2505 of 23S rRNA (Fig. 5c). This critical, water-mediated contact between a 
macrolide molecule and the ribosome, which has never been reported before, illuminates the 
previously obscure role of the dimethyl-amino moiety of desosamine in macrolide binding to the 
ribosome. Consistent with our observations, re-evaluation of the electron density maps of 
previously published ribosome-macrolide complex structures revealed the presence of this same 
water molecule; a peak of positive electron density can be seen in the same location in all structures 
with resolution ≤ 2.7Å22,32. However, it is the high quality of our structural data, which allows for 
interpretation of this density peak as a water molecule and reveals the possibly critical role of this, 
previously overlooked, player in macrolide binding. 
 
Structural basis for Erm-mediated macrolide resistance. 
The discovery of a key water molecule that mediates macrolide binding to the ribosome and the 
solved structure of the A2058-dimethylated ribosome allows a conceptually new rationalization of 
Erm-mediated macrolide resistance in molecular terms. In the unmethylated ribosome, the N6-
amino group of the A2058 residue serves as an H-bond donor that shares one proton with the H2O 
oxygen atom (Fig. 5c, e). This water molecule, in turn, shares one of its protons with the G2505 
phosphate and the other proton with the dimethyl-amino group of a macrolide. Dimethylation (but 
not monomethylation) of the N6-amino group of the A2058 by Erm-methyltransferases makes 
coordination of this water molecule impossible due to the inability of the A2058 dimethyl-amino 
group to serve as a proton donor. Furthermore, one of the m62A2058 methyl groups would 
physically displace the water molecule (Fig. 5d, e), leaving the dimethyl-amine of desosamine 
without the mediator of its interaction with the G2505 phosphate. The lack of such interaction in 
the A2058-dimethylated ribosome would have a strong negative effect on the free energy of the 
drug-ribosome complex leading to macrolide resistance. The same water molecule could also be 
  
Svetlov, M.S. et al. Manuscript  P a g e  | 10 of 27 
observed in the current structure of wild-type ribosome in the absence of a macrolide. Therefore, 
it is conceivable that it could be important for normal ribosome functioning by stabilizing the local 
structure of the 23S rRNA. Displacement of this water molecule by dimethylation of A2058 and 
the resulting alteration in the local 23S rRNA structure and/or the chemical makeup of the NPET 
could potentially account for reduced fitness of cells expressing Erm methyltransferase, linked to 
aberrant translation of specific proteins41. 
Besides the Erm-catalyzed dimethylation of A2058, mutations of this nucleotide to guanine, 
cytosine, or uracyl also result in macrolide resistance42,43. The discovered water-mediated 
interaction of macrolides with the ribosome allows re-evaluation of the mechanism of antibiotic 
resistance caused by these mutations (Supplementary Fig. 8a). In silico modeling of the A2058 
mutations reveals that pyrimidine bases at this position would be placed too far from the 
desosamine moiety of a macrolide to establish any interactions with the drug (including water-
mediated contacts) (Supplementary Fig. 8c, d). Replacing A2058 with guanine was proposed to 
lead to a steric clash with the C4 carbon of the macrolactone ring (Supplementary Fig. 8b)22. Our 
structures show that in addition to this mechanism, G2058 would not be able to coordinate the 
critical molecule of water the same way as adenine because the O6 atom of guanine cannot serve 
as an H-bond donor (Supplementary Fig. 8b). 
Erm-mediated dimethylation of A2058 residue is the major clinical mechanism of bacterial 
resistance not only to macrolides but also to lincosamides and type B streptogramins. Comparison 
of our structure of the A2058-dimethylated 70S ribosome with the previously reported structure 
of the ribosome-bound lincosamide antibiotic clindamycin24 reveals a significant steric clash 
between one of the methyl groups of m62A2058 and the 2´- and 3´-OH groups of the 7-chloro-1-
methylthio-lincosamine moiety of the drug (Supplementary Fig. 9a, b). In contrast to macrolides 
and type B streptogramins, a similar high level of resistance to lincosamides could be achieved not 
only by dimethylation but also by monomethylation of A205829,44. Due to the sp2 geometry of the 
N6-atom, the single methyl group of the monomethylated A2058 residue can exist in two 
alternative conformations: syn-methyl (with the methyl group oriented towards the Watson-Crick 
edge of the nucleotide) and anti-methyl (with the methyl group rotated towards the N7-atom of 
the adenine base )45. Importantly, it is only the syn-methyl conformation of the N6-methyl group 
of monomethylated A2058 that would clash with the ribosome-bound lincosamide drug, whereas 
the N6-methyl group in the anti-methyl conformation not only avoids the clash but could also 
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retain all H-bonding capabilities potentially critical for the lincosamide drug binding 
(Supplementary Fig. 9b). However, because of a steric hindrance from the N7-atom of adenine, 
the syn-methyl conformation is energetically more favorable than the anti-methyl conformation45. 
Unlike macrolides, lincosamides, whose binding to the ribosome is characterized by 3-order of 
magnitude lower affinity46,47, apparently cannot overcome the energy needed to re-orient the 
methyl group of N6-monomethylated A2058 into unfavorable anti-methyl conformation. Thus, 
N6-monomethylation of the A2058 is likely to cause resistance to lincosamides via the same steric 
hindrance mechanism as the dimethylation of the same adenine residue (Supplementary Fig. 9a, 
b). 
Interestingly, similar superpositioning of the structure of the A2058-dimethylated ribosome with 
the published structure of type B streptogramin antibiotic quinupristin complexed to the 
ribosome26 does not show any overlap between m62A2058 and the drug (Supplementary Fig. 9c, 
d). Moreover, the N6-dimethyl is located on the opposite side of the A2058 nucleotide relative to 
the closest dimethyl-amino-phenylalanine moiety of the ribosome-bound quinupristin 
(Supplementary Fig. 9d). This moiety likely forms a Van-der-Waals contact with the N3 atom of 
the A2058 residue. However, because the A2058 nucleotides in the two superimposed structures 
have the same conformations, the N6-dimethylation of A2058 is unlikely to perturb this contact 
(Supplementary Fig. 9d). Overall, structural analysis shown in Supplementary Fig. 9c does not 
reveal disruptions of any critical contacts of the drug with the ribosome that could be caused by 
Erm-catalyzed A2058 dimethylation and, thus, does not offer a straightforward explanation for the 
molecular mechanism of the Erm-mediated streptogramin B resistance, which still remains 
enigmatic. Although Erm-mediated dimethylation of A2058 renders bacterial ribosomes resistant 
to macrolides, lincosamides, and streptogramins B, the actual mechanism of resistance at a 
molecular level appears to be different for each class of NPET-targeting antibiotics. 
Altogether, our structural study uncovering the molecular mechanism of Erm-mediated resistance 
could be a starting point for the rational knowledge-based development of new MLSB antibiotics 
active against challenging drug-resistant pathogens. This quest will be likely additionally 
stimulated by the recently discovered new combinatorial approaches for the synthesis of novel 
macrolides48, streptogramins49, and other drugs. Interestingly, all previous attempts to make 
macrolides active against Erm-modified ribosomes relied on derivatization of the existing 
macrolides to provide additional anchoring points that improved their overall affinity50. However, 
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very few of the derivatizations affected the desosamine likely due to its importance in overall drug 
binding. Unfortunately, the affinities of the resulting semi-synthetic macrolides of a newer 
generation (such as telithromycin or solithromycin) to the modified ribosome are too low for 
successful use of these drugs for the treatment of infections caused by pathogens that express Erm 
methyltransferase19,51,52. Now, when the precise role of the desosamine sugar in macrolide binding 
to the ribosome is uncovered, this information may become instrumental in the designing of 
macrolides that can overcome Erm-mediated resistance. 
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ACCESSION NUMBERS 
Coordinates and structure factors were deposited in the RCSB Protein Data Bank with accession 
codes: 6XHV for the A2058-dimethylated T. thermophilus 70S ribosome in complex with mRNA, 
aminoacylated A-site Phe-NH-tRNAPhe, aminoacylated P-site fMet-NH-tRNAiMet, and deacylated 
E-site tRNAPhe; 6XHW for the A2058-unmethylated T. thermophilus 70S ribosome in complex 
with mRNA, aminoacylated A-site Phe-NH-tRNAPhe, aminoacylated P-site fMet-NH-tRNAiMet, 
and deacylated E-site tRNAPhe; 6XHX for the T. thermophilus 70S ribosome in complex with 
erythromycin and protein Y; 6XHY for the T. thermophilus 70S ribosome in complex with 
telithromycin, mRNA, aminoacylated A-site Phe-NH-tRNAPhe, aminoacylated P-site fMet-NH-
tRNAiMet, and deacylated E-site tRNAPhe. 
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FIGURE LEGENDS 
 
Figure 1 | Thermus thermophilus HB27 strain expressing Erm-like methyltransferase. (a) 
Mono- and dimethylation of the A2058 residue in the domain V of the 23S rRNA by the Erm-class 
methyltransferases results in high-level resistance to macrolides. (b) Multiple sequence alignment 
of several known Erm-methyltransferases from mesophilic bacteria (ErmC (Staphylococcus 
aureus), ErmB (Streptococcus pneumonia), and PikR2 (S. venezuelae)) with the Erm-like protein 
from moderately thermophilic B. thermophilum (ErmBth, optimal growth temperature 40-45°C). 
For complete sequence alignment, refer to Supplementary Fig. 2. A part of the amino acid 
sequences responsible for the binding of the donor of methyl groups (SAM) is shown. Conserved 
residues are highlighted in red. Black triangles point to the amino acid residues that coordinate 
SAM at the active site of the enzymes. (c) Schematic map of the plasmid vector used for the 
expression of ErmBth methyltransferase in Thermus thermophilus (Tth) HB27 cells. This vector 
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designed to replicate in Tth carries the hygromycin B resistance marker hph under the control of 
PslpA promoter (grey) and the ErmBth gene under the control of Parg promoter (orange). (d) Primer 
extension analysis of the A2058-dimethylation in the 23S rRNA isolated from Erm(+) Tth cells. 
Cells transformed either with the empty pBGAA1 vector (lane 1) or with the pErmBTH plasmid 
were grown in the absence (lane 2) or in the presence of 0.5x MIC of ERY (lane 3). Reverse 
transcriptase stalls at N6-dimethylated A2058 and produces truncated cDNA (marked with the red 
arrow). Sequencing lanes are shown. (e) ErmBth-catalyzed A2058 dimethylation is stimulated by 
ERY in the growth medium. The concentration of ERY was varied from 1/128 to 1/2 MIC, and 
cells were grown at 48°C. The isolated rRNA was analyzed by primer extension in the presence 
of dATP, dCTP, dTTP, and ddGTP. While the dideoxynucleotide ddGTP causes reverse 
transcription to stop at position C2055 on all templates, the N6-dimethylation arrest cDNA 
synthesis at position A2058 of the 23S rRNA. The reason for the appearance of the ‘readthrough’ 
cDNA product (indicated by an asterisk) is unclear but could result from either contamination of 
the reaction with dGTP, or nucleotide misincorporation at C2055 during reverse transcription at 
50°C. The extent of dimethylation is calculated as a ratio of the intensity of the A2058-specific 
band to the sum of the intensities of the A2058-, C2055- and the readthrough bands (after 
background subtraction) and indicated below the gel. 
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Figure 2 | Electron density maps of N6-dimethylated (top) and unmethylated (bottom) A2058 
residue of the 23S rRNA in T. thermophilus 70S ribosome. (a, c) Unbiased Fo-Fc (grey and 
green mesh) and (b, d) 2Fo-Fc (blue mesh) electron difference Fourier maps of A2058 residue in 
the T. thermophilus 70S ribosome contoured at 3.0σ and 1.0σ, respectively, and viewed from two 
different perspectives. Grey mesh shows the Fo-Fc map after refinement with the entire modified 
nucleotide omitted. Green mesh, reflecting the presence of methyl groups, shows the Fo-Fc electron 
density map after refinement with the nucleotide A2058 built as a regular unmethylated adenine. 
The refined models of N6-dimethylated (a, b) or unmethylated (c, d) adenine nucleotide are 
displayed in the corresponding electron density maps. Carbon atoms are colored blue for the 
methylated A2058 and light blue for the unmethylated A2058; nitrogens are dark blue; oxygens 
are red, phosphorus atoms are green.  
  
  
Svetlov, M.S. et al. Manuscript  P a g e  | 18 of 27 
 
Figure 3 | Structure of the Erm-modified 70S ribosome reveals the absence of any significant 
rearrangements in the macrolide binding pocket. (a, b) Location of the Erm-modified 
nucleotide A2058 (yellow) carrying two methyl groups (orange) in the nascent peptide exit tunnel 
(NPET) of the Tth 70S ribosome relative to tRNAs and ribosomal proteins L4 (teal) and L22 (blue) 
viewed as cross-cut sections through the ribosome. The 30S subunit is shown in light yellow, the 
50S subunit is in light blue, the mRNA is in magenta, and the A-, P-, and E-site tRNAs are colored 
green, dark blue, and orange, respectively. The phenylalanyl and formyl-methionyl moieties of the 
A- and P-site tRNAs are colored magenta and blue, respectively. (c, d) Close-up views of the 23S 
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rRNA nucleotides lining the macrolide binding pocket in the NPET. Nucleotides of the Erm-
modified and unmodified ribosomes are shown in blue and light blue, respectively. The N6-
dimethylated A2058 residue is highlighted in yellow with methyl groups shown in orange. E. coli 
nucleotide numbering is used. H-bonds are shown with dashed lines.  
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Figure 4 | Superposition of the structures of A2058-methylated 70S ribosome and 
unmethylated 70S ribosome-ERY complex. (a) Chemical structure of classical macrolide 
antibiotic erythromycin (ERY). The standard numbering of carbon atoms is shown in grey. (b) 
Superposition of the current structure of A2058-methylated 70S ribosome with the new high-
resolution structure of ribosome-bound ERY. Methylated A2058 residue is shown in blue with the 
methyl groups highlighted in orange. Unmethylated A2058 residue is shown in light blue. All 
structures were aligned based on domain V of the 23S rRNA. (c, d) Close-up views of the 
desosamine 2´-OH group (c) and the desosamine dimethyl-amino moiety (d) relative to the methyl 
  
Svetlov, M.S. et al. Manuscript  P a g e  | 21 of 27 
groups on m62A2058 residue. Note that there are no sterical clashes between the methyl groups of 
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Figure 5 | A water molecule mediates the interaction of macrolides with the ribosome. (a, b) 
High-resolution 2Fo-Fc electron density maps (blue mesh) of ribosome-bound ERY (green, A) and 
TEL (magenta, B) show that the dimethyl-amino group of a macrolide is rotated towards A2058 
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and forms an H-bond with a water molecule (yellow) that is tightly coordinated by the exocyclic 
N6-amino group of A2058 and the phosphate of G2505. The view in the middle insets is from the 
top along the H-bond, connecting the G2505 phosphate with the water. (c) Detailed arrangement 
of the H-bonds formed by the desosamine sugar of a macrolide (green) with 23S rRNA (blue) of 
the ribosome via a water molecule (yellow). Hydrogens are colored white; nitrogens blue; oxygens 
red (except for the water). H-bonds are shown with dashed lines. (d) Superpositioning of the new 
structures of ribosome-bound ERY with the new structure of the A2058-dimethylated 70S 
ribosome showing the clash between one of the m26A2058 methyl groups and the water molecule. 
(e) Schematic diagram showing the molecular mechanism of resistance of A2058-dimethylated 
ribosomes to macrolide antibiotics. Note that due to the inability of the dimethyl-amino group of 
the m62A2068 residue to serve as an H-bond donor, it cannot participate in the coordination of the 
water molecule on the ribosome. Moreover, the methyl groups physically displace the water 
molecule leaving the G2505 phosphate and the dimethyl-amino group of macrolide desosamine 
without an H-bond partner. 
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